Cargando…
Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study
BACKGROUND: As a potential target receptor tyrosine kinase, mesenchymal-epithelial transition factor (MET) exhibits high aberrant expression across various tumors. This study aimed to evaluated the safety, tolerability, efficacy and pharmacokinetics (PK) of BPI-9016M, a novel tyrosine kinase inhibit...
Autores principales: | Hu, Xingsheng, Cui, Xinge, Wang, Ziping, Liu, Yunpeng, Luo, Ying, Zhong, Wei, Zhao, Hui, Yao, Mengxing, Jiang, Da, Wang, Mingxia, Chen, Minjiang, Zheng, Xin, Ding, Lieming, Wang, Yang, Yuan, Xiaobin, Wu, Pengxiang, Hu, Bei, Han, Xiaohong, Shi, Yuankai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088252/ https://www.ncbi.nlm.nih.gov/pubmed/37041472 http://dx.doi.org/10.1186/s12885-022-10500-y |
Ejemplares similares
-
First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer
por: Hu, Xingsheng, et al.
Publicado: (2020) -
BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1
por: Zhang, Panpan, et al.
Publicado: (2018) -
Radiosensitizing effect of c-Met kinase inhibitor BPI-9016M in esophageal squamous cell carcinoma cells in vitro and in vivo
por: Jiang, Chenxue, et al.
Publicado: (2021) -
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
por: Santarpia, Mariacarmela, et al.
Publicado: (2021) -
Recurrent PTPRZ1‐MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases
por: Chai, Rui‐Chao, et al.
Publicado: (2021)